Literature DB >> 2374681

Relative survival rates after alternative therapies for uveal melanoma.

J M Seddon1, E S Gragoudas, K M Egan, R J Glynn, S Howard, R G Fante, D M Albert.   

Abstract

Survival in a group of 556 patients with uveal melanoma treated by proton beam irradiation with a median follow-up of 5.3 years was compared with that of 238 patients enucleated during the same 10-year period as irradiated patients (July 1975 to December 1984) with a median follow-up of 8.8 years, and 257 patients enucleated during the preceding 10 years (January 1965 to June 1975) with a median follow-up of 17.0 years. Adjustments were made for known prognostic factors including age, tumor location, tumor height, and clinical estimate of tumor diameter (for enucleated patients this was estimated in a regression equation relating histologic to clinical measurement). The overall rate ratio for all cause mortality was 1.2 (95% confidence interval, 0.9-1.6) for the concurrent enucleation series versus proton beam, and 1.6 (95% confidence interval, 1.2-2.1) for the earlier enucleation series versus proton beam. Relative rates of metastatic death, cancer death, and all cause mortality comparing alternative treatments were found to vary with time after treatment. Interval-specific rate ratios were evaluated using proportional hazards models fitted to separate time intervals after treatment. For all three outcomes, rate ratios were over two and statistically significant for the first 2 years after treatment and closer to one and nonsignificant after year 6 comparing the two enucleation groups with proton beam. Results suggest that treatment choice has little overall influence on survival in patients with uveal melanoma.

Entities:  

Mesh:

Year:  1990        PMID: 2374681     DOI: 10.1016/s0161-6420(90)32512-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  30 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 2.  The Zimmerman-McLean-Foster hypothesis: 25 years later.

Authors:  A D Singh; I G Rennie; T Kivela; S Seregard; H Grossniklaus
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

3.  1996 Jules Gonin Lecture of the Retina Research Foundation. Long-term results after proton irradiation of uveal melanomas.

Authors:  E S Gragoudas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-05       Impact factor: 3.117

Review 4.  Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review.

Authors:  W A Manschot; R van Strik
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

5.  Proton therapy for uveal melanomas and other eye lesions.

Authors:  J E Munzenrider
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

6.  Evolution of Care of Orbital Tumors with Radiation Therapy.

Authors:  Myrsini Ioakeim-Ioannidou; Shannon M MacDonald
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-24

7.  Management of uveal melanoma: a consensus-based provincial clinical practice guideline.

Authors:  E Weis; T G Salopek; J G McKinnon; M P Larocque; C Temple-Oberle; T Cheng; J McWhae; R Sloboda; M Shea-Budgell
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

8.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

Review 9.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

10.  Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.

Authors:  Evangelos S Gragoudas; Anne Marie Lane; John Munzenrider; Kathleen M Egan; Wenjun Li
Journal:  Trans Am Ophthalmol Soc       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.